HOME >> MEDICINE >> NEWS
Researchers discover novel pathway of inflammation that contributes to lung damage in CF patients

lung infection is the leading reason children visit doctors.

"Studies over the last decade have suggested that an excessive inflammatory response to infection occurs in CF. Clinical trials of non-specific anti-inflammatory therapies have shown some clinical benefit, but significant side effects have limited their utility," said co-author Joseph Pilewski, MD, associate professor of Medicine, Pediatrics and Cell Biology and Physiology at the University of Pittsburgh School of Medicine. "This work identifies a target for more specific regulation of the inflammatory pathways that ultimately contribute to lung damage in CF. Modulating this pathway could lead to a safer and more effective anti-inflammatory therapy for CF and perhaps other inflammatory lung diseases."

Dr. Pilewski also is co-director of the Adult Cystic Fibrosis Program at the Antonio J. and Janet Palumbo Cystic Fibrosis Center at Children's Hospital of Pittsburgh, and Medical Director of the Lung Transplant Program at the University of Pittsburgh Medical Center.

Dr. Kolls' team is investigating gene-based strategies to probe the immune system's ability to fight infection in the T-cell depleted setting. In mice when T-cells are depleted, the mice are able to protect themselves against infections when given an experimental therapy that takes certain proteins secreted by T-cells the growth factor, IL-17, for example and reconstitutes them into the system. Such an approach might someday treat infections which do not respond well to antibiotics, such as pneumocystis.

The investigation of cytokines is also leading to better understanding of their role in inflammation in the lungs of patients with cystic fibrosis.

Dr. Kolls said, "I think that if we can understand the inflammation processes, we can make an impact on their lives." Dr. Kolls and his team's discovery could also have applications with Multiple Sclerosis, as well as Inflammatory Bowel Disease.

Mor
'"/>

Contact: Melanie Finnigan
Melanie.Finnigan@chp.edu
412-692-5502
Children's Hospital of Pittsburgh
30-Jun-2005


Page: 1 2 3

Related medicine news :

1. Researchers suggest TB screening for all international adoptees
2. Researchers find vitamin B1 deficiency key to vascular problems for diabetic patients
3. Researchers link metal ions to neurodegenerative disease
4. Researchers develop criteria to detect bone mass deficiencies in children with chronic diseases
5. Researchers call for investigation into links between khat use and psychiatric disorders
6. Researchers use MRI to predict recovery after spinal cord injury
7. Researchers find deadly prescription drug effects 6 years before FDA
8. Researchers investigate impact of lifestyle on GI health
9. Researchers begin randomized double-blind trial of airway bypass treatment for emphysema
10. Researchers discover how antibiotic inhibits bacterial growth
11. Researchers urge caution in using ESAs for cancer-related anemia

Post Your Comments:
(Date:8/3/2015)... ... August 03, 2015 , ... ... 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb B2B Awards ... brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics product was ...
(Date:8/3/2015)... ... 03, 2015 , ... To date, many pharmaceutical and biotech ... of benefits, allowing them to gain access to capabilities that cannot be found ... resources, get access to innovation and ensure timely introduction of product into the ...
(Date:8/3/2015)... ... August 03, 2015 , ... A recent survey by ... of Hispanics believe people can positively affect their diabetes, few look beyond diet ... making diet changes was important. Far fewer participants mentioned the need for exercise ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... and the largest online retailer of nutritional supplements, has officially opened the ... for 11 awards in the following categories:, ,     Brand ...
(Date:8/3/2015)... Venice Beach, CA (PRWEB) , ... August 03, ... ... supporting individuals suffering from ALS and amputation , AUGUST 3, 2015 – Since ... DIY category in March 2015, Not Impossible – an organization whose mission is ...
Breaking Medicine News(10 mins):Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4
(Date:8/3/2015)... JUPITER, Fla. , Aug. 3, 2015 /PRNewswire/ ... announced initiation of its second clinical development program ... drug candidate, CL-H1T.  CL-H1T contains ... is being developed as a treatment for migraine ... "Many patients with migraine headaches ...
(Date:8/3/2015)... and FLORHAM PARK, N.J. , ... once-daily naldemedine met its primary and secondary endpoints in ... of opioid-induced constipation (OIC) in adult patients with chronic ... mu-opioid receptor antagonist (PAMORA). This is the third Phase ... key secondary endpoints. Study results showed that ...
(Date:8/3/2015)... ZIONA, Israel , August 3, 2015 /PRNewswire/ ... today announced it received the statistical analysis of results from ... administered in the BVX-005 phase II trial which took place ... which did not exist at the time of the study- ... that caused the epidemic in the United States ...
Breaking Medicine Technology:Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
Cached News: